DexCom, Inc. Aktie (A0D9T1) - Kurs Nasdaq - MarketScreener (2024)

FAQs

Is DexCom a good stock to buy now? ›

Dexcom has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings. The average price target for Dexcom is $104.68. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.

Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, Baillie Gifford & Co, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Capital Research Global Investors, Sands Capital Management, Llc, Fmr Llc, Geode Capital Management, Llc, and VFINX - Vanguard 500 Index Fund Investor ...

Its bottom-line is projected to rise 17.1% year-over-year for 2024, while Wall Street anticipates its top line to improve by 19.4%. One analyst revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0 to $1.78 per share.

Investing.com -- Dexcom slashed its guidance Thursday after reporting second-quarter revenue fell short of estimates as the diabetes management solutions provider flagged weaker execution of key strategies.

Dexcom's revenue increased 15% from $871.3 million a year earlier, according to a release. The company reported net income of $143.5 million, up from $115.9 million in the same period last year.

DexCom has a market cap or net worth of $28.96 billion as of August 22, 2024. Its market cap has decreased by -32.70% in one year.

Kevin Sayer is the Chairman of the Board of Directors, President and Chief Executive Officer of Dexcom.

In clinical studies, the results from home glucose testing devices are considered accurate if they pass the 20 rule (also known as the %20/20 rule). If the lab result is greater than 5.5 mmol/L (100 mg/dL) the CGM value must be no more than 20% higher or lower¹.

Does DexCom charge a monthly fee? ›

Convenience is at your fingertips with our Subscription program. Get automated shipments sent right to your door every 3 months for just $299 a month. A great option for those without insurance coverage, our Subscription plan offers the same price every month without the hassle of reordering supplies.

We have been experiencing an extremely high failure rate for dexcom g6 cgm sensors since switching from g5. The g6 system is significantly better than g5 in most ways when all is working, but the sensors are apt to fail at least 25% of the time or higher.

- The Dexcom G7 is contraindicated for MRI/CT/diathermy. The Dexcom G7 system components should be removed during magnetic resonance imaging (MRI) or high-frequency electrical heat (diathermy) treatment.

This order, therefore, classifies the Dexcom G6 Continuous Glucose Monitoring System, and substantially equivalent devices of this generic type, into Class II under the generic name “Integrated continuous glucose monitoring system.”

DXCM INVESTOR ALERT: DexCom, Inc. has been Sued for Securities Fraud – Investors that Suffered Losses are Urged to Contact BFA Law before October 21 (NASDAQ:DXCM)

(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 10.91% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.93%. Dexcom's revenue in 2024 is $3,934,800,000.

DexCom stock (symbol: DXCM) underwent a total of 1 stock split. The stock split occurred on June 13th, 2022.

This audio is auto-generated. Please let us know if you have feedback. UPDATE: May 31, 2022: Dexcom said on Tuesday that it isn't in “active discussions regarding a merger transaction at this time,” following a report that the company was looking to acquire Insulet.